why choose us

Clinical Trials Search

Showing 20,510 of 132,963 result(s)
SuRxgWell: The Use of RxWell to Minimize the Impact of Mood Disorders on the Recovery of Surgical Patients

Status: Completed

Condition: Mood Disorders

Interventions: During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download t

Date: 2022-07-26

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Status: Completed

Condition: Non Small Cell Lung Cancer

Interventions: Additional core needle biopsy (CNB) passes from either the primary lung or a metastatic site will be obtained for tumors amenable to an additional pas

Date: 2022-07-26

Bipolar Transcranial Alternating Current Stimulation (tACS)

Status: ACTIVE_NOT_RECRUITING

Condition: Bipolar Disorder

Interventions: Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes.
tACS will be delivered by passing a small electric

Date: 2022-07-26

CNS Correlates of Extended Sleep Restriction

Status: Completed

Condition: Sleep Restriction

Interventions: Brain PET with [11C]ER176.
[11C]ER176 is a PET ligand that images TSPO.

Date: 2022-07-26

IL13 Signaling in Allergic Asthma

Status: Completed

Condition: Asthma, Allergic

Interventions:

Date: 2022-07-26

The Pharmacodynamics of Cannabinoid-Caffeine Combinations

Status: Completed

Condition: Behavioral Pharmacology of Cannabinoids

Interventions: Placebo will be orally self-administered by study participants.

Date: 2022-07-26

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Status: Completed

Condition: Ovarian Cancer Stage IV

Interventions: 300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51

Date: 2022-07-26

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Status: Completed

Condition: Colon Adenocarcinoma

Interventions: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (

Date: 2022-07-26

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma

Status: Completed

Condition: Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Given IV

Date: 2022-07-26

Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Status: COMPLETED

Condition: Platinum-resistant Ovarian Cancer

Interventions: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRP? and CD40L (SIRP? -Fc-CD40L) linked via a human Fc.

Date: 2022-07-26